Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 PublicationRecord Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 AdverseEventsReport
.... 15.4 BaselineMeasureEvidence
.... 15.5 BaselineMeasureReport
.... 15.6 BaselineVariablesList
.... 15.7 BookCitation
.... 15.8 BookPartCitation
.... 15.9 CertaintyOfEvidence
.... 15.10 Classification
.... 15.11 CohortDefinition
.... 15.12 Comment
.... 15.13 ComparativeBaselineMeasureEvidence
.... 15.14 ComparativeEvidence
.... 15.15 ComparativeEvidenceReport
.... 15.16 ComparativeEvidenceReportExpanded
.... 15.17 ComparativeEvidenceReportSubject
.... 15.18 ComparativeEvidenceSynthesisReport
.... 15.19 ComparativeParticipantFlowEvidence
.... 15.20 ComparatorGroup
.... 15.21 ComparatorOnlyEvidence
.... 15.22 Comparison
.... 15.23 CompositeRating
.... 15.24 ConceptualCohortDefinition
.... 15.25 ConceptualComparatorDefinition
.... 15.26 ConceptualExposureDefinition
.... 15.27 DatabaseCitation
.... 15.28 DatabaseEntryCitation
.... 15.29 DatasetCitation
.... 15.30 DateAsRating
.... 15.31 DichotomousIntendedOutcome
.... 15.32 EndpointAnalysisPlan
.... 15.33 EvidenceAssessment
.... 15.34 EvidenceList
.... 15.35 EvidenceReport
.... 15.36 EvidenceReportPackage
.... 15.37 EvidenceReportSubject
.... 15.38 EvidenceSynthesisEvidence
.... 15.39 ExposureGroup
.... 15.40 GroupAssignment
.... 15.41 GroupR6
.... 15.42 Guideline
.... 15.43 InterventionOnlyEvidence
.... 15.44 JournalArticleCitation
.... 15.45 M11ReportContainer
.... 15.46 M11ReportSection01
.... 15.47 M11ReportSection02
.... 15.48 M11ReportSection03
.... 15.49 M11ReportSection04
.... 15.50 M11ReportSection05
.... 15.51 M11ReportSection06
.... 15.52 M11ReportSection07
.... 15.53 M11ReportSection08
.... 15.54 M11ReportSection09
.... 15.55 M11ReportSection10
.... 15.56 M11ReportSection11
.... 15.57 M11ReportSection12
.... 15.58 M11ReportSection13
.... 15.59 M11ReportSection14
.... 15.60 M11ResearchStudy
.... 15.61 MetaanalysisEligibilityCriteria
.... 15.62 MetaanalysisOutcomeDefinition
.... 15.63 MetaanalysisStudyGroup
.... 15.64 NetEffectContribution
.... 15.65 NetEffectContributionList
.... 15.66 NetEffectContributions
.... 15.67 NetEffectEstimate
.... 15.68 NonComparativeEvidence
.... 15.69 OutcomeDefinition
.... 15.70 OutcomeImportance
.... 15.71 OutcomeList
.... 15.72 OutcomeMeasureReport
.... 15.73 OutcomeVariablesList
.... 15.74 ParticipantFlowEvidence
.... 15.75 ParticipantFlowEvidenceVariable
.... 15.76 ParticipantFlowReasonEvidenceVariable
.... 15.77 ParticipantFlowReport
.... 15.78 ParticipantFlowVariablesList
.... 15.79 PICOSpecification
.... 15.80 PICOTaggedComposition
.... 15.81 PICOTaggedEvidence
.... 15.82 PreprintCitation
.... 15.83 Rating
.... 15.84 Recommendation
.... 15.85 RecommendationAction
.... 15.86 RecommendationEligibilityCriteria
.... 15.87 RecommendationJustification
.... 15.88 RecommendationPlan
.... 15.89 RecommendationRating
.... 15.90 ResearchStudyDataDictionary
.... 15.91 ResearchStudySite
.... 15.92 ResearchStudySupport
.... 15.93 RiskOfBias
.... 15.94 SearchResults
.... 15.95 SearchStrategy
.... 15.96 SingleStudyEvidence
.... 15.97 SoaPlanDefinition
.... 15.98 SoftwareCitation
.... 15.99 StatisticModel
.... 15.100 StudyComponent
.... 15.101 StudyDesign
.... 15.102 StudyEligibilityCriteria
.... 15.103 StudyGroup
.... 15.104 StudyRegistryRecord
.... 15.105 SummaryOfFindings
.... 15.106 SummaryOfNetEffect
.... 15.107 SystematicReview
.... 15.108 SystematicReviewEligibilityCriteria
.... 15.109 SystematicReviewExcludedStudies
.... 15.110 SystematicReviewIncludedStudies
.... 15.111 VariableDefinition
.... 15.112 WebPageCitation
.... 15.113 ArtifactAssessmentCompared
.... 15.114 ArtifactAssessmentDateAsRating
.... 15.115 ArtifactPublicationStatus
.... 15.116 ArtifactRecorder
.... 15.117 CharacteristicTiming
.... 15.118 CiteAs
.... 15.119 GuidelineRegistration
.... 15.120 NumberAnalyzed
.... 15.121 RelatesToClassifier
.... 15.122 RelatesToWithQuotation
.... 15.123 RelativeOutcomeImportance
.... 15.124 RelevantForAutomatedMatching
.... 15.125 ResearchStudyExcludedStudy
.... 15.126 ResearchStudyIncludedStudy
.... 15.127 ResearchStudyIsLowInterventionTrial
.... 15.128 ResearchStudyIsRareDisease
.... 15.129 ResearchStudyM11AmendmentDetail
.... 15.130 ResearchStudyM11AmendmentScopeImpact
.... 15.131 ResearchStudyM11Approval
.... 15.132 ResearchStudyM11ProtocolAmendment
.... 15.133 ResearchStudyNumberOfStudiesIdentified
.... 15.134 ResearchStudyNumberOfStudiesIncluded
.... 15.135 ResearchStudySaeReportingMethod
.... 15.136 ResearchStudySearchStrategy
.... 15.137 ResearchStudySponsorConfidentialityStatement
.... 15.138 ResearchStudyStudyAmendment
.... 15.139 ResearchStudySystematicReviewEligibilityCriteria
.... 15.140 ResearchStudyVersionDate
.... 15.141 StatisticModelExpression
.... 15.142 StatisticModelIncludeIf
.... 15.143 Desirability Codes Value Set
.... 15.144 EBMonFHIR Profile Name Value Set
.... 15.145 Evidence Rating System Classifier Codes Value Set
.... 15.146 ICH M11 Amendment Details Statement Value Set
.... 15.147 ICH M11 Amendment Scope Enrollment Value Set
.... 15.148 ICH M11 Amendment Scope Value Set
.... 15.149 ICH M11 Reason for Amendment Value Set
.... 15.150 ICH M11 Trial Phase Value Set
.... 15.151 ICH M11 Yes No Value Set
.... 15.152 Limited M11 Section Codes Value Set
.... 15.153 PICO Classification Value Set
.... 15.154 Recommendation Justification Classifier Codes Value Set
.... 15.155 Research Study Document Types Value Set
.... 15.156 ResearchStudy Classifier Value Set
.... 15.157 Search Strategy Characteristic Value Set
.... 15.158 UDP Identifier Type Value Set
.... 15.159 UDP Party Role Type Value Set
.... 15.160 Desirability Code System
.... 15.161 EBMonFHIR Profile Name Code System
.... 15.162 Evidence Rating System Classifier Code System
.... 15.163 Research Study Document Types Code System
.... 15.164 Search Strategy Characteristic Code System
.... 15.165 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.166 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.167 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.168 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.169 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.170 179899
.... 15.171 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.172 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.173 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.174 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.175 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.176 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.177 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.178 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.179 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.180 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.181 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.182 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.183 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.184 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.185 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.186 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.187 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.188 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.189 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.190 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.191 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.192 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.193 27979893 6. Glycemic Targets.
.... 15.194 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.195 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.196 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.197 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.198 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.199 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.200 30467172 Finding my inner Wonder Woman.
.... 15.201 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.202 33008778 Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.
.... 15.203 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.204 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.205 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.206 367832
.... 15.207 367833
.... 15.208 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.209 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.210 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.211 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.212 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.213 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.214 Add-on Amlodipine at 6 weeks
.... 15.215 Adults hospitalized with COVID-19 pneumonia
.... 15.216 Adults with diabetes mellitus type 2
.... 15.217 Adults with type 2 diabetes and CVD and CKD
.... 15.218 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.219 Adverse event free and hypertension control
.... 15.220 Adverse event free and hypertension control at 12 weeks
.... 15.221 Adverse Events Report for NCT03421379
.... 15.222 Adverse Events Report for NCT03640312
.... 15.223 Age
.... 15.224 Age with comparator
.... 15.225 Age with intervention
.... 15.226 Aircraft Type
.... 15.227 Aircraft Type with comparator
.... 15.228 Aircraft Type with intervention
.... 15.229 Altitude
.... 15.230 Altitude comparing intervention vs. comparator
.... 15.231 Altitude for enrolled group
.... 15.232 Altitude for screened group
.... 15.233 Altitude with comparator
.... 15.234 Altitude with intervention
.... 15.235 Analysis of formalin-fixed paraffin-embedded and blood and blood samples (NCT05327010)
.... 15.236 Analyzed Group in PARACHUTE Trial
.... 15.237 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.238 Anticoagulation for COVID-19 Combined RCTs PrePrint
.... 15.239 Assess emergent resistant mutations (NCT05327010)
.... 15.240 Baseline Characteristics Report for NCT03421379
.... 15.241 Baseline Characteristics Report for NCT03640312
.... 15.242 Baseline Characteristics Report for QUARTET Trial
.... 15.243 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.244 Baseline Measures List for PARACHUTE Trial
.... 15.245 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.246 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.247 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.248 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.249 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.250 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.251 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.252 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.253 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.254 BP-CONTROL Cardiovascular Outcomes Component: intensive versus standard blood-pressure control in adults at increased cardiovascular risk
.... 15.255 BP-CONTROL Master Protocol: blood-pressure targets in adults at increased cardiovascular risk
.... 15.256 Candesartan 8 mg once daily
.... 15.257 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.258 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.259 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.260 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.261 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.262 Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)
.... 15.263 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.264 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.265 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.266 Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)
.... 15.267 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.268 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.269 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.270 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.271 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.272 Citation for EBMonFHIR Implementation Guide
.... 15.273 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.274 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.275 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.276 Clinical benefit rate (CBR) (NCT05327010)
.... 15.277 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.278 Comparative Evidence Report Expanded for QUARTET USA Trial
.... 15.279 Comparative Evidence Report for QUARTET USA Trial
.... 15.280 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.281 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.282 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.283 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.284 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.285 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.286 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.287 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.288 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.289 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.290 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.291 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.292 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.293 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.294 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.295 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.296 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.297 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.298 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.299 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.300 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.301 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.302 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.303 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.304 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.305 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.306 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.307 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.308 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.309 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.310 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.311 ComparatorDefinition: Standard care
.... 15.312 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.313 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.314 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.315 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.316 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.317 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.318 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.319 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.320 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.321 Computable_Publishing_LLC
.... 15.322 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.323 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.324 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.325 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.326 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.327 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.328 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.329 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.330 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.331 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.332 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.333 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.334 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.335 ConceptualCohortDefinition: Nonfatal stroke
.... 15.336 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.337 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.338 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.339 ConceptualCohortDefinition: Severe obesity
.... 15.340 ConceptualCohortDefinition: T1DM or T2DM
.... 15.341 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.342 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.343 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.344 ConceptualCohortDefinition_Cardiovascular_event
.... 15.345 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.346 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.347 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.348 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.349 Correlate baseline mutations with treatment response (NCT05327010)
.... 15.350 Correlate changes in ctDNA variant allele frequencies with response (NCT05327010)
.... 15.351 Correlate mutation profiles with tumor sequencing (NCT05327010)
.... 15.352 Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response (NCT05327010)
.... 15.353 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.354 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.355 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.356 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.357 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.358 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.359 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.360 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.361 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.362 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.363 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.364 CTIS2025-523977-40-00 Eligibility Criteria - ARMYDA Study on Coronary Plaque Change with Semaglutide in Diabetes with ACS
.... 15.365 DatabaseCitation: Citation for FEvIR Platform
.... 15.366 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.367 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.368 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.369 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.370 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.371 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.372 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.373 declined randomization in PARACHUTE Study
.... 15.374 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.375 Delany-Moretlwe 2022 clinical trial
.... 15.376 Diabetes treatment medication
.... 15.377 Diastolic blood pressure at 12 weeks
.... 15.378 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.379 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.380 DichotomousIntendedOutcome: New onset depression
.... 15.381 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.382 DichotomousIntendedOutcome: Remission of diabetes
.... 15.383 DichotomousIntendedOutcome: Treatment with opioids
.... 15.384 DIO: Mortality
.... 15.385 Duration of response (NCT05327010)
.... 15.386 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.387 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.388 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.389 Eligibility criteria for NMA_Diabetes
.... 15.390 Eligibility Criteria for QUARTET USA Trial
.... 15.391 Enrolled Group for QUARTET USA Trial
.... 15.392 Enrolled Group PARACHUTE Trial
.... 15.393 Ethnic Group
.... 15.394 Ethnic Group with comparator
.... 15.395 Ethnic Group with intervention
.... 15.396 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.397 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.398 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.399 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.400 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.401 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.402 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.403 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.404 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.405 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.406 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.407 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.408 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.409 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.410 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.411 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.412 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.413 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.414 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.415 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.416 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.417 EvidenceReportSectionCode Value Set
.... 15.418 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.419 EvidenceVariable Handling Extension Value Set
.... 15.420 EvidenceVariable: case_id
.... 15.421 EvidenceVariable: Patient id
.... 15.422 EvidenceVariable: Time of measurement
.... 15.423 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.424 Example of a ResearchStudySite
.... 15.425 Example of statistical model expression
.... 15.426 Excluded from PARACHUTE Study
.... 15.427 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.428 ExposureVariable: Age (as continuous variable)
.... 15.429 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.430 Family History of Parachute Use
.... 15.431 Family History of Parachute Use with comparator
.... 15.432 Family History of Parachute Use with intervention
.... 15.433 Frequent Flier
.... 15.434 Frequent Flier with comparator
.... 15.435 Frequent Flier with intervention
.... 15.436 Gene expression profiling (NCT05327010)
.... 15.437 GLP-1 RA Group in Adults with type 2 diabetes
.... 15.438 GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.439 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.440 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.441 Glucagon Nasal Powder (Experimental)
.... 15.442 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.443 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.444 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.445 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.446 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.447 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.448 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.449 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.450 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.451 GroupAssignment: Quadpill vs. Candesartan
.... 15.452 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.453 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.454 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.455 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.456 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.457 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.458 Health Survey Score Total
.... 15.459 Health Survey Score Total comparing intervention vs. comparator
.... 15.460 Health Survey Score Total with comparator
.... 15.461 Health Survey Score Total with intervention
.... 15.462 Health Survey Score-Mental Health Subscore
.... 15.463 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.464 Health Survey Score-Mental Health Subscore with comparator
.... 15.465 Health Survey Score-Mental Health Subscore with intervention
.... 15.466 Health Survey Score-Physical Health Subscore
.... 15.467 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.468 Health Survey Score-Physical Health Subscore with comparator
.... 15.469 Health Survey Score-Physical Health Subscore with intervention
.... 15.470 Health-related Quality of Life (NCT03640312)
.... 15.471 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.472 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.473 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.474 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.475 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.476 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.477 Height
.... 15.478 Height with comparator
.... 15.479 Height with intervention
.... 15.480 High Blood Pressure Medication Value Set
.... 15.481 History of Acrophobia
.... 15.482 History of Acrophobia with comparator
.... 15.483 History of Acrophobia with intervention
.... 15.484 History of Broken Bones
.... 15.485 History of Broken Bones with comparator
.... 15.486 History of Broken Bones with intervention
.... 15.487 History of Parachute Use
.... 15.488 History of Parachute Use with comparator
.... 15.489 History of Parachute Use with intervention
.... 15.490 Hypertension Control at 12 weeks
.... 15.491 ICD-10-GM Terminale Codes
.... 15.492 Incidence of adverse events (NCT05327010)
.... 15.493 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.494 Injury Severity Score 30 days after Impact with comparator
.... 15.495 Injury Severity Score 30 days after Impact with intervention
.... 15.496 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.497 Injury Severity Score on Impact with comparator
.... 15.498 Injury Severity Score on Impact with intervention
.... 15.499 International vs Domestic Flight
.... 15.500 International vs Domestic Flight with comparator
.... 15.501 International vs Domestic Flight with intervention
.... 15.502 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.503 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.504 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.505 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.506 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.507 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.508 Investigator
.... 15.509 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.510 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.511 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.512 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.513 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.514 Jumping from aircraft with empty backpack
.... 15.515 Jumping from aircraft with parachute
.... 15.516 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.517 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.518 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.519 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.520 M11 Report for M11ResearchStudy Template
.... 15.521 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.522 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template
.... 15.523 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.524 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template
.... 15.525 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.526 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template
.... 15.527 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.528 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template
.... 15.529 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.530 M11 Report Section 13 (Glossary) for M11ResearchStudy Template
.... 15.531 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.532 M11 Report Section 14 (References) for M11ResearchStudy Template
.... 15.533 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.534 M11 Report Section 2 (Introduction) for M11ResearchStudy Template
.... 15.535 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.536 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template
.... 15.537 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.538 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template
.... 15.539 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.540 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template
.... 15.541 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.542 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template
.... 15.543 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.544 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template
.... 15.545 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.546 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template
.... 15.547 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.548 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template
.... 15.549 M11ResearchStudy Template
.... 15.550 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.551 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.552 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.553 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.554 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.555 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.556 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.557 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.558 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.559 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.560 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.561 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.562 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.563 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.564 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.565 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.566 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.567 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.568 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.569 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.570 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.571 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.572 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.573 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.574 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.575 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.576 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.577 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.578 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.579 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.580 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.581 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.582 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.583 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.584 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.585 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.586 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.587 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.588 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.589 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.590 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.591 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.592 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.593 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.594 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.595 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.596 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.597 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.598 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.599 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.600 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.601 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.602 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.603 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.604 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.605 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.606 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.607 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.608 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.609 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.610 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.611 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.612 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.613 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.614 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.615 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.616 MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes
.... 15.617 Major adverse cardiovascular events (composite endpoint)
.... 15.618 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.619 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.620 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.621 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.622 Mean Change in Serum Creatinine (NCT03640312)
.... 15.623 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.624 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.625 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.626 Mean Change in Serum Potassium (NCT03640312)
.... 15.627 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.628 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.629 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.630 Mean Change in Serum Sodium (NCT03640312)
.... 15.631 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.632 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.633 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.634 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.635 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.636 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.637 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.638 Mean Systolic Blood Pressure (NCT03640312)
.... 15.639 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.640 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.641 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.642 Median Age of Parachute Intervention Group
.... 15.643 Medication Adherence (NCT03640312)
.... 15.644 Medication Adherence at 12 weeks
.... 15.645 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.646 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.647 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.648 Mental Health T Score at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.649 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.650 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.651 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.652 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.653 Mortality at 14 days
.... 15.654 NCT03421379 Eligibility Criteria
.... 15.655 NCT03640312 Eligibility Criteria
.... 15.656 NCT04401202 Eligibility Criteria
.... 15.657 NCT04401202_Enrollment_Group
.... 15.658 NCT05327010 Eligibility Criteria
.... 15.659 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.660 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.661 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.662 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.663 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.664 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.665 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.666 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.667 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.668 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.669 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.670 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.671 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.672 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.673 NHANES SEQN Respondent Sequence Number
.... 15.674 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.675 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.676 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.677 NT-proBNP Study Data Dictionary
.... 15.678 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.679 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.680 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.681 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.682 Objective response rate (ORR) (NCT05327010)
.... 15.683 Organ support-free days
.... 15.684 Outcome Importance Rating 100 of All-cause mortality
.... 15.685 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.686 Outcome Importance Rating 5 of New onset depression
.... 15.687 Outcome Importance Rating 5 of Remission of diabetes
.... 15.688 Outcome Importance Rating 5 of Treatment with opioids
.... 15.689 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.690 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.691 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.692 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.693 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.694 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.695 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.696 Outcome Measure List for QUARTET USA Trial
.... 15.697 Outcome Measure Report for QUARTET USA Trial
.... 15.698 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.699 Outcome Measures Report for NCT03421379
.... 15.700 Outcome Measures Report for NCT03640312
.... 15.701 Outcome Variables List for PARACHUTE Trial
.... 15.702 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.703 Outcome: Death or Major Traumatic Injury on Impact
.... 15.704 Outcome: Injury Severity Score 30 days after Impact
.... 15.705 Outcome: Injury Severity Score on Impact
.... 15.706 OutcomeDefinition for All-cause mortality
.... 15.707 OutcomeDefinition for Body weight
.... 15.708 OutcomeDefinition for Cardiovascular mortality
.... 15.709 OutcomeDefinition for End-stage kidney disease
.... 15.710 OutcomeDefinition for Health-related quality of life
.... 15.711 OutcomeDefinition for Heart failure
.... 15.712 OutcomeDefinition for Nonfatal myocardial infarction
.... 15.713 OutcomeDefinition for Nonfatal stroke
.... 15.714 OutcomeDefinition for Serious hyperglycaemia
.... 15.715 OutcomeDefinition for Severe gastrointestinal events
.... 15.716 OutcomeDefinition: Injury Severity Score on Impact
.... 15.717 OutcomeDefinition: All-cause mortality
.... 15.718 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.719 OutcomeDefinition: Body weight
.... 15.720 OutcomeDefinition: Cardiovascular mortality
.... 15.721 OutcomeDefinition: Diabetes in remission
.... 15.722 OutcomeDefinition: Diabetic ketoacidosis
.... 15.723 OutcomeDefinition: End-stage kidney disease
.... 15.724 OutcomeDefinition: Genital infection
.... 15.725 OutcomeDefinition: HbA1c at 12 months
.... 15.726 OutcomeDefinition: HbA1c at 24 months
.... 15.727 OutcomeDefinition: HbA1c at 36 months
.... 15.728 OutcomeDefinition: HbA1c at 6 months
.... 15.729 OutcomeDefinition: HbA1c at 60 months
.... 15.730 OutcomeDefinition: Health-related quality of life
.... 15.731 OutcomeDefinition: Heart failure
.... 15.732 OutcomeDefinition: Mortality at 14 days
.... 15.733 OutcomeDefinition: New onset depression
.... 15.734 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.735 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.736 OutcomeDefinition: Nonfatal stroke
.... 15.737 OutcomeDefinition: Serious hyperglycaemia
.... 15.738 OutcomeDefinition: Severe gastrointestinal events
.... 15.739 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.740 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.741 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.742 OutcomeVariable: HbA1c at 12 months
.... 15.743 OutcomeVariable: HbA1c at 24 months
.... 15.744 OutcomeVariable: HbA1c at 36 months
.... 15.745 OutcomeVariable: HbA1c at 6 months
.... 15.746 OutcomeVariable: HbA1c at 60 months
.... 15.747 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.748 OutcomeVariable: New onset depression
.... 15.749 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.750 OutcomeVariable: Remission of diabetes
.... 15.751 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.752 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.753 OutcomeVariable_All_cause_mortality
.... 15.754 OutcomeVariable_Treatment_with_opioids
.... 15.755 Overall survival (NCT05327010)
.... 15.756 PARACHUTE Trial baseline characteristics
.... 15.757 PARACHUTE Trial non participants
.... 15.758 PARACHUTE trial participant flow report
.... 15.759 PARACHUTE Trial Participants
.... 15.760 PARACHUTE Trial Participants assigned an empty backpack
.... 15.761 PARACHUTE trial participants assigned parachute
.... 15.762 PARACHUTE Trial Participants available for randomization
.... 15.763 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.764 PARACHUTE Trial Participants randomized into groups
.... 15.765 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.766 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.767 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.768 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.769 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.770 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.771 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.772 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.773 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.774 PARACHUTE Trial Participants that declined randomization
.... 15.775 PARACHUTE Trial Participants with no contact at 30 days
.... 15.776 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.777 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.778 PARACHUTE Trial Results
.... 15.779 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.780 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.781 Participant Flow Report for NCT03421379
.... 15.782 Participant Flow Report for NCT03640312
.... 15.783 Participant Flow Report for QUARTET USA Trial
.... 15.784 Participant Flow Variables List for PARACHUTE Trial
.... 15.785 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.786 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.787 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.788 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.789 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.790 ParticipantFlowMeasure: Exclusion from analysis
.... 15.791 ParticipantFlowMeasure: Inclusion in analysis
.... 15.792 Participants Excluded from PARACHUTE Study
.... 15.793 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.794 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.795 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.796 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.797 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.798 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.799 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.800 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.801 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.802 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202)
.... 15.803 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint
.... 15.804 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint
.... 15.805 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint
.... 15.806 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.807 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.808 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.809 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.810 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.811 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.812 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.813 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.814 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.815 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.816 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.817 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.818 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.819 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.820 Physical Health T Score at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.821 PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk
.... 15.822 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.823 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.824 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.825 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.826 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.827 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.828 Placebo
.... 15.829 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.830 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.831 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.832 Progression-free survival (NCT05327010)
.... 15.833 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.834 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.835 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.836 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.837 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.838 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.839 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.840 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.841 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.842 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.843 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.844 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.845 Quadpill once daily
.... 15.846 QUARTET USA Trial Control Group
.... 15.847 QUARTET USA Trial Quadpill group
.... 15.848 randomized into groups for PARACHUTE Trial
.... 15.849 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.850 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.851 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.852 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.853 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.854 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.855 Reasons for exclusion from QUARTET USA Trial
.... 15.856 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.857 Recommendation Justification Code System
.... 15.858 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.859 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.860 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.861 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.862 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.863 Remdesivir
.... 15.864 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.865 ResearchStudy Classifier Code System
.... 15.866 Results Section for NCT03421379
.... 15.867 Results Section for NCT03640312
.... 15.868 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.869 Risk of Bias Assessment of PARACHUTE trial
.... 15.870 Risk Of Bias Type Value Set
.... 15.871 Screened Group PARACHUTE Trial
.... 15.872 Search Strategy for NMA_Diabetes
.... 15.873 SearchResults: PubMed search for Wonder Woman
.... 15.874 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.875 SearchStrategy: PubMed search for Wonder Woman
.... 15.876 Sex
.... 15.877 Sex with comparator
.... 15.878 Sex with intervention
.... 15.879 SGLT2 inhibitors Group in Adults with diabetes mellitus type 2
.... 15.880 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.881 SMR-excluded Tlayjeh H J Infect Public Health 33008778
.... 15.882 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.883 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.884 Spanish or English Value Set
.... 15.885 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.886 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.887 StudyEligibilityCriteria for M11Report Example
.... 15.888 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.889 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.890 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.891 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.892 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.893 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.894 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.895 Summary of Findings - QUARTET USA Trial
.... 15.896 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.897 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.898 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.899 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.900 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.901 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.902 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.903 Systolic blood pressure at 12 weeks
.... 15.904 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
.... 15.905 Time to integration of results in a recommendation
.... 15.906 Treatment-induced changes in phospho-protein signaling (NCT05327010)
.... 15.907 VariableDefinition: Comparator
.... 15.908 VariableDefinition: Condition(s)
.... 15.909 VariableDefinition: Date of birth
.... 15.910 VariableDefinition: Date of measurement
.... 15.911 VariableDefinition: Gender
.... 15.912 VariableDefinition: NTproBNP
.... 15.913 VariableDefinition: Unit
.... 15.914 Velocity
.... 15.915 Velocity comparing intervention vs. comparator
.... 15.916 Velocity for enrolled group
.... 15.917 Velocity for non participant group
.... 15.918 Velocity with comparator
.... 15.919 Velocity with intervention
.... 15.920 WebPageCitation: A HEvKA Update Summary
.... 15.921 Weight
.... 15.922 Weight with comparator
.... 15.923 Weight with intervention